Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues
https://www.zacks.com/stock/news/2236717/bayer-bayry-q4-earnings-top-crop-science-unit-drives-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236717
Mar 06, 2024 - Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
0
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502
Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
0
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
https://www.zacks.com/stock/news/2243015/intellia-ntla-begins-dosing-in-phase-iii-attr-amyloidosis-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243015
Mar 19, 2024 - Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
0
EXEL or REGN: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2252785/exel-or-regn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2252785
Apr 09, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
https://www.zacks.com/commentary/2261192/top-stock-reports-for-danaher-regeneron-pharmaceuticals-palo-alto-networks?cid=CS-ZC-FT-research_daily-2261192
Apr 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
0
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
https://www.zacks.com/stock/news/2265330/will-these-5-drug-biotech-stocks-beat-q1-earnings-forecast?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2265330
Apr 30, 2024 - Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
0
5 Big Drug Stocks That May Continue to Outperform in 2024
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
0
Best Momentum Stocks to Buy for January 3rd
https://www.zacks.com/commentary/2204746/best-momentum-stocks-to-buy-for-january-3rd?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2204746
Jan 03, 2024 - SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
0
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
https://www.zacks.com/stock/news/2205668/are-medical-stocks-lagging-aclaris-therapeutics-acrs-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2205668
Jan 04, 2024 - Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
0